Literature DB >> 27408302

Toxicity of Low-Dose Intermittent Isotretinoin in Recalcitrant Acne.

A Kumar1, V K Kumar2.   

Abstract

BACKGROUND: Isotretinoin, an oral retinoid, has been utilized to achieve long term remissions in cases of recalcitrant acne. In the conventional dosage schedule, the use of oral isotretinoin has been limited by the occurrence of biochemical abnormalities such as hypertriglyceridaemia and impaired liver function tests and radiological changes consistent with diffuse idiopathic skeletal hyperostosis. Low-dose intermittent regimen of oral isotretinoin has been evolved as a cost effective alternative to the conventional dosage regimen in cases of acne. This study addresses the issue of adverse effects of low-dose intermittent isotretinoin and the safety of this regimen.
METHODS: A total of 60 cases of recalcitrant acne were included in the study. Baseline haematological, biochemical and radiological investigations were carried out. Low-dose intermittent isotretinoin was instituted in a dose of 0.5 mg/kg/day for one week in every four weeks for six months. The investigations were repeated at the end of six months therapy. RESULT: High triglyceride levels occurred in 5% of cases whereas impaired liver function tests and skeletal hyperostosis of the spine were not observed in any case after low-dose intermittent isotretinoin.
CONCLUSION: The low-dose intermittent regimen in cases of acne may be utilized to limit the systemic toxicity of oral isotretinoin.

Entities:  

Keywords:  Isotretinoin; Low-dose intermittent regimen; Recalcitrant acne

Year:  2011        PMID: 27408302      PMCID: PMC4921320          DOI: 10.1016/S0377-1237(10)80038-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  14 in total

Review 1.  Isotretinoin effects on bone.

Authors:  J J DiGiovanna
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

Review 2.  Treatment of acne with isotretinoin: recommendations based on Australian experience.

Authors:  Alan J Cooper
Journal:  Australas J Dermatol       Date:  2003-05       Impact factor: 2.875

Review 3.  Psychosocial effects of acne.

Authors:  D R Thomas
Journal:  J Cutan Med Surg       Date:  2004       Impact factor: 2.092

4.  The effectiveness of intermittent isotretinoin treatment in mild or moderate acne.

Authors:  Y Kaymak; N Ilter
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-11       Impact factor: 6.166

5.  A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris.

Authors:  Rachel S Altman; Lawrence J Altman; Jeffrey S Altman
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

6.  Continued occurrence of Accutane-exposed pregnancies.

Authors:  M A Honein; L J Paulozzi; J D Erickson
Journal:  Teratology       Date:  2001-09

7.  High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.

Authors:  Nicolas Rodondi; Roger Darioli; Albert-Adrien Ramelet; Daniel Hohl; Vincent Lenain; Jean Perdrix; Vincent Wietlisbach; Walter F Riesen; Thomas Walther; Laurent Medinger; Pascal Nicod; Béatrice Desvergne; Vincent Mooser
Journal:  Ann Intern Med       Date:  2002-04-16       Impact factor: 25.391

Review 8.  Uses and complications of isotretinoin therapy.

Authors:  C N Ellis; K J Krach
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

9.  Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris.

Authors:  K Sardana; V K Garg; V N Sehgal; S Mahajan; P Bhushan
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-01-09       Impact factor: 6.166

10.  Antibiotic-resistant acne: lessons from Europe.

Authors:  J I Ross; A M Snelling; E Carnegie; P Coates; W J Cunliffe; V Bettoli; G Tosti; A Katsambas; J I Galvan Peréz Del Pulgar; O Rollman; L Török; E A Eady; J H Cove
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.